Best of ASCO - 2014 Annual Meeting



Attend this session at the
2017 ASCO Annual Meeting!

Session: Gynecologic Cancer

Type: Poster Session

Time: Saturday June 3, 1:15 PM to 4:45 PM

Location: Hall A

A randomized phase III trial of cisplatin with or without S-1 in patients with FIGO IVB, recurrent, or persistent cervical cancer: An Asian study.

Cervical Cancer

Gynecologic Cancer

2017 ASCO Annual Meeting

Abstract No:

Poster Board Number:
Poster Session (Board #349)

J Clin Oncol 35, 2017 (suppl; abstr 5527)

Author(s): Soyi Lim, Kazunori Ochiai, Yoichi Aoki, Daisuke Aoki, Shoji Kamiura, Hao Lin, Yasuhiro Fujiwara, Soon Do Cha, Jae Hoon Kim, Byoung Kim, Yasuyuki Hirashima, Keiichi Fujiwara, Young Tak Kim, Seok-Mo Kim, Hyun Hoon Chung, Ting-Chang Chang, Toshiharu Kamura, Ken Takizawa, Masahiro Takeuchi, Soon-Beom Kang; Department of Obstetrics and Gynecology, Gachonuniversity Gil Medical Center, Incheon, Republic of Korea; The Jikei University School of Medicine, Tokyo, Japan; Graduate School of Medical Science, University of the Ryukyus, Okinawa, Japan; Keio University School of Medicine, Tokyo, Japan; Osaka International Cancer Institute, Osaka, Japan; Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; National Cancer Center Hospital East, Tokyo, Japan; Keimyung University School of Medicine, Daegu, Republic of Korea; Yonsei University College of Medicine, Seoul, South Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Shizuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Japan; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Chonnam National University Hwasun Hospital, Hwasun, South Korea; Seoul National University College of Medicine, Seoul, South Korea; Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; Kurume University School of Medicine, Fukuoka, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Clinical Medicine, School of Pharmacy, Kitasato University, Tokyo, Japan; Konkuk University School of Medicine, Seoul, Republic of Korea

Abstract Disclosures


Background: A combination of S-1, an oral fluoropyrimidine, plus cisplatin has been used for advanced gastric cancer in Asia and EU, and lung cancer in Japan. It also evaluated in advanced or recurrent cervical cancer in a phase II setting. We conducted a randomized phase III trial to compare the efficacy and safety of S-1 plus cisplatin with those of cisplatin alone in recurrent or persistent after treatment and FIGO IVB cervical cancer patients. Methods: Stage IVB, recurrent or persistent cervical cancer patients aged ≥ 20 years, ECOG PS 0–1 and adequate organ function were randomly assigned (1:1) to receive S-1 (80–120 mg daily, according to BSA, day 1–14) plus cisplatin (50 mg/m2 on day 1) (study group) or cisplatin alone (50 mg/m2 on day 1) (control group) every 3 weeks. Treatment was continued until disease progression. In all, 360 patients (at least 296 events) with a hazard ratio (HR) for death of 0.72 were required for a two-sided alpha of 5% and power of 80% under 2 years of recruitment and 1.5 years of follow-up. Stratification factors included recurrence in previously irradiated field, previous platinum-based therapy, and institution. Primary endpoint was OS based on intent-to-treat principle, and secondary endpoints were PFS, overall response rate (ORR), and safety. Results: In all, 375 patients were assigned to the study (n = 189) and control (n = 186) groups. Rate of previous platinum-based therapy was 64%. The median survival time was 21.9 and 19.5 months (95% CI, 18.6–25.8 and 17.0–24.3) with the use of unstratified log-rank test in the study and control groups, respectively (log-rank P = 0.125; HR, 0.84; 95% CI, 0.67–1.05). Significant increases in median PFS (7.3 vs. 4.9 months; log-rank P < 0.001; HR, 0.62) and ORR (43.8 vs. 20.1%, P < 0.001) were observed in the study group. Adverse events (grade≥3) were frequent in the study group (80.9 vs. 41.7%) with neutropenia (52.7%), anemia (34.6%), and leukopenia (32.4%) being the most common events. Conclusions: Compared with cisplatin alone, S-1 plus cisplatin did not significantly improve OS but increased ORR, prolonged PFS, and had tolerable safety of patients with stage IVB, recurrent or persistent cervical cancer. Clinical trial information: NCT00770874

Other Abstracts in this Sub-Category:


1. An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers.

Meeting: 2017 ASCO Annual Meeting Abstract No: 5504 First Author: Antoine Hollebecque
Category: Gynecologic Cancer - Cervical Cancer


2. Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study.

Meeting: 2017 ASCO Annual Meeting Abstract No: 5514 First Author: Jan H.M. Schellens
Category: Gynecologic Cancer - Cervical Cancer


3. Association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival.

Meeting: 2017 ASCO Annual Meeting Abstract No: 5525 First Author: Winald R. Gerritsen
Category: Gynecologic Cancer - Cervical Cancer